Ilyas K. Colombowala, MD, FACC, FHRS
Cardiac Electrophysiology · Houston, TX · colombowala.com
EP Staff Education Clinical Staff Ilyas Colombowala, MD, FACC, FHRS →
Patient library → ← Main site

Device

Transvenous ICD Overview

The traditional implantable cardioverter-defibrillator — generator under the clavicle, defibrillator lead in the RV with one or two shock coils. Covers single vs dual chamber, primary vs secondary prevention, lead architecture, DFT testing, and zone programming.

Common issues / troubleshooting

  • ▸T-wave oversensing in the VF zone causing inappropriate shocks — recheck sensing vector and decay delay.
  • ▸Lead noise from a fractured high-voltage conductor masquerading as VT/VF.
  • ▸Inappropriate shocks during rapidly conducted AF — extend detection intervals and use SVT discriminators.
  • ▸Failed first shock with low shock impedance suggesting coil-to-coil short or insulation breach.
  • ▸Phantom shocks — non-events on stored EGM but patient reports a jolt; usually anxiety or other muscle stimulus.
Heart Generator Shock coil
Transvenous ICD — generator with a shock coil on the lead

A transvenous ICD does everything a pacemaker does, plus it can deliver anti-tachycardia pacing (ATP) and high-voltage therapy. The hardware looks similar to a pacemaker but the can is larger to house the shock capacitors and the RV lead is a thicker, dual-purpose device with one or two integrated shock coils.

How the system works

  • The generator senses, paces, runs ATP, charges the capacitor, and delivers a shock between defined electrode pairs (usually RV coil to can, sometimes including SVC coil).
  • The RV lead carries low-voltage pacing/sensing electrodes at the tip plus the high-voltage shock coils.
  • Sensing happens through a dedicated sense pair with auto-gain control — sensitivity dynamically adjusts after each beat to catch fine VF without oversensing T-waves.
  • Detection runs through programmed zones with rate cutoffs and discriminators; therapy delivery follows a programmed sequence.

Types / Variants

Single-chamber transvenous

One lead (RV). Used when no atrial pacing is needed and SVT discrimination from the RA isn’t required (e.g., chronic AF, no bradycardia indication).

Dual-chamber transvenous

RA lead plus RV ICD lead. Adds atrial pacing capability and improves SVT vs VT discrimination via atrial activity. Chosen when there’s a separate pacing indication, suspected SVT/VT overlap, or HFrEF with a subset that might progress.

Lead architecture

  • Single-coil: RV coil only — simpler, less hardware in the SVC, easier to extract later. Adequate DFT in most patients.
  • Dual-coil: RV + SVC coils — slightly larger shock vector, historically default but losing ground because extraction is harder.

FDA-approved platforms: Medtronic Cobalt / Crome / Visia AF, Abbott Gallant / Entrant, Boston Scientific Resonate / Vigilant.

Indications & candidate selection

Primary prevention

  • HFrEF with LVEF <=35% on guideline-directed medical therapy for at least 3 months, NYHA II-III, life expectancy >1 year with reasonable functional status.
  • Post-MI EF <=30% beyond 40 days.
  • Inherited arrhythmia syndromes with high-risk features (HCM, LQTS, Brugada, ARVC) per condition-specific risk scores.

Secondary prevention

  • Survived cardiac arrest from VT/VF without a reversible cause.
  • Sustained VT with structural heart disease.
  • Syncope with inducible sustained VT at EP study in the right substrate.

Key programming considerations

  • VT zone: typically 170-200 bpm. ATP first (burst, 8 beats at 88% of VT cycle length), then shock if persistent.
  • VF zone: typically >=200-220 bpm. Charge during the detection window, deliver shock; consider an ATP attempt during charging on Medtronic platforms.
  • Detection durations: longer intervals before therapy (e.g., 30/40 or 18/24) reduce inappropriate shocks without delaying needed therapy — confirmed across multiple landmark trials.
  • SVT discriminators: onset, stability, morphology, AV relationship (dual chamber). Turn them on within the VT zone; turn them off in the VF zone — never delay therapy for true VF.
  • Pacing parameters: same considerations as a pacemaker; minimise RV pacing if AV conduction is intact.

What to know in the lab

  • The RV ICD lead is stiffer than a pacing lead — gentle curves, no kinks. Confirm slack but not redundancy at the can.
  • Position the RV coil entirely below the tricuspid valve — coil crossing the valve degrades sensing and risks TR.
  • Check pacing threshold, sensing, and pacing impedance before testing shock impedance.
  • Shock impedance between 30 and 90 ohms confirms a complete circuit; out-of-range readings warrant repositioning before declaring done.
  • DFT testing is no longer routine for de novo left-pectoral implants — reserve for right-sided implants, suspected high-DFT substrate, or systems where the shock vector is questionable.

Common issues & troubleshooting

  • T-wave oversensing — check sensing vector, post-pace blanking, and decay delay; consider reprogramming sensing vector before assuming lead issue.
  • High-voltage lead fracture — abrupt impedance change, noise on the EGM, often non-physiologic short intervals counted as VT/VF. Fluoroscopy to look for conductor extrusion at the header or under the clavicle.
  • Inappropriate AF shocks — push detection durations longer, ensure SVT discriminators are armed, optimise rate control.
  • Failed first shock — verify shock impedance, check vector polarity, escalate energy and reposition coils only if needed.
  • Phantom shocks — pull device stored EGMs; no detected event = no shock delivered. Address anxiety, evaluate for other stimulus sources (TENS units, electrical work).

Manufacturer reference

Last reviewed by Dr. Colombowala on May 22, 2026.

Not medical advice. This page is educational. Your situation may differ — discuss it with Dr. Colombowala or your treating physician before making decisions.

Source: